{"nctId":"NCT00251004","briefTitle":"Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients","startDateStruct":{"date":"2005-10"},"conditions":["Kidney Transplantation","Graft Rejection"],"count":833,"armGroups":[{"label":"Low-dose Everolimus Group","type":"EXPERIMENTAL","interventionNames":["Drug: Everolimus","Drug: Cyclosporine A (CsA)","Drug: Basiliximab","Drug: Corticosteroids"]},{"label":"High-dose Everolimus Group","type":"EXPERIMENTAL","interventionNames":["Drug: Everolimus","Drug: Cyclosporine A (CsA)","Drug: Basiliximab","Drug: Corticosteroids"]},{"label":"Control Group","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Mycophenolic Acid (MPA)","Drug: Cyclosporine A (CsA)","Drug: Basiliximab","Drug: Corticosteroids"]}],"interventions":[{"name":"Everolimus","otherNames":["Certican, Zotress"]},{"name":"Mycophenolic Acid (MPA)","otherNames":["Myfortic"]},{"name":"Cyclosporine A (CsA)","otherNames":["Neoral"]},{"name":"Basiliximab","otherNames":["Simulect"]},{"name":"Corticosteroids","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female patients of any race between 18 to 70 years old (inclusive)\n* Patients who gave written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Recipients of multi-organ transplantation\n* Recipients of a primary cadaveric or primary non-human leucocyte antigen (HLA) identical living donor kidney transplantation.\n* Graft cold ischemia time greater than 40 hours.\n\nOther protocol-defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Composite Efficacy Endpoints - 12 Month Analysis","description":"The primary efficacy endpoint was the 12 month analysis of primary efficacy failure defined as a composite endpoint including treated biopsy proven acute rejection (BPAR), graft loss, death or loss to follow-up. A treated BPAR episode was defined as a biopsy graded IA, IB, IIA, IIB, or III that was treated with anti-rejection therapy. Graft loss was defined as the allograft was presumed to be lost on the day the patient started dialysis and was not able to subsequently be removed from dialysis as well as re-transplant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"60","spread":null},{"groupId":"OG002","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"38","spread":null},{"groupId":"OG002","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With the Composite Incidence of Graft Loss, Death or Loss to Follow up at 12 Months Post-transplantation","description":"Graft loss was defined as graft loss (the allograft was presumed to be lost on the day the patient started dialysis and was not able to subsequently be removed from dialysis) and re-transplant.\n\nA loss to follow-up patient in the composite endpoint of graft loss, death or loss to follow-up (the main secondary efficacy endpoint) was a patient who did not experience graft loss or death from day 1 and whose last day of contact was prior to study day 316.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.6","spread":null},{"groupId":"OG001","value":"9.7","spread":null},{"groupId":"OG002","value":"9.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Non-inferiority Analysis on Percentage of Participants With Composite Efficacy Endpoints","description":"The primary efficacy endpoint was the 12 month analysis of primary efficacy failure defined as a composite endpoint including treated biopsy proven acute rejection (BPAR), graft loss, death or loss to follow-up. In the definition of composite efficacy failure, loss to follow-up includes patients who did not experience treated BPAR, graft loss or death on or after day 1 and whose last day of contact was prior to day 316, the start day of the 12 month visit window.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.1","spread":null},{"groupId":"OG001","value":"21.5","spread":null},{"groupId":"OG002","value":"25.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Non-inferiority Analysis of Renal Function, Calculated by Glomerular Filtration Rate (cGFR) Using Modification of Diet in Renal Disease (MDRD) Formula","description":"Modification of Diet in Renal Disease (MDRD) formula is:\n\nGFR \\[mL/min/1.73m\\^2\\] = 186.3\\*(C\\^-1.154)\\*(A\\^-0.203)\\*G\\*R where\n\n* C is the serum concentration of creatinine \\[mg/dL\\],\n* A is patient age at sample collection date \\[years\\],\n* G=0.742 when gender is female, otherwise G=1,\n* R=1.21 when race is black, otherwise R=1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.66","spread":null},{"groupId":"OG001","value":"51.41","spread":null},{"groupId":"OG002","value":"52.24","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":176,"n":274},"commonTop":["Oedema peripheral","Constipation","Nausea","Hypertension","Anaemia"]}}}